Islet Transplantation

Policy # 00007  
Original Effective Date: 08/26/2002  
Current Effective Date: 05/11/2020

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Chronic Intermittent Intravenous Insulin Therapy (CIIT) is addressed separately in medical policy 00015.

Note: Allogeneic Pancreas Transplant is addressed separately in medical policy 00092.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and  
• Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider autologous pancreas islet transplantation as an adjunct to a total or near total pancreatectomy in patients with chronic pancreatitis to be eligible for coverage.**

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers allogeneic islet transplantation for the treatment of type 1 diabetes to be investigational.*

Based on review of available data, the Company considers autologous or allogeneic islet transplantation for all other indications to be investigational.*
Islet Transplantation

Policy # 00007
Original Effective Date: 08/26/2002
Current Effective Date: 05/11/2020

Background/Overview
Islet Transplantation
In autologous islet transplantation during the pancreatectomy procedure, islet cells are isolated from the resected pancreas using enzymes, and a suspension of the cells is injected into the portal vein of the patient's liver. Once implanted, the beta cells in these islets begin to make and release insulin.

Allogeneic islet transplantation potentially offers an alternative to whole-organ pancreas transplantation. In the case of allogeneic islet cell transplantation, cells are harvested from a deceased donor's pancreas, processed, and injected into the recipient's portal vein. Up to three donor pancreas transplants may be required to achieve insulin independence. However, a limitation of islet transplantation is that two or more donor organs are usually required for successful transplantation, although experimentation with single-donor transplantation is occurring. A pancreas that is rejected for whole-organ transplant is typically used for islet transplantation. Therefore, islet transplantation has generally been reserved for patients with frequent and severe metabolic complications who have consistently failed to achieve control with insulin-based management. Allogeneic transplantation may be performed in the radiology department.

In 2000, a modified immunosuppression regimen increased the success of allogeneic islet transplantation. This regimen is known as the "Edmonton protocol."

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation Title 21, parts 1270 and 1271. Allogeneic islet cells are included in these regulations.

Rationale/Source
Performed in conjunction with pancreatectomy, autologous islet transplantation is proposed to reduce the likelihood of insulin-dependent diabetes. Allogeneic islet cell transplantation is also being investigated as a treatment or cure for patients with type 1 diabetes.
Islet Transplantation

Policy # 00007
Original Effective Date: 08/26/2002
Current Effective Date: 05/11/2020

For individuals with chronic pancreatitis undergoing total or near-total pancreatectomy who receive autologous pancreas islet transplantation, the evidence includes case series and systematic reviews. The relevant outcomes are overall survival, change in disease status, medication use, resource utilization, and treatment-related morbidity. Autologous islet transplants are performed in the context of total or near-total pancreatectomies to treat intractable pain from chronic pancreatitis. The procedure appears to decrease significantly the incidence of diabetes after total or near-total pancreatectomy in patients with chronic pancreatitis. Also, this islet procedure is not associated with serious complications and is performed in patients who are already undergoing a pancreatectomy procedure. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with type 1 diabetes who receive allogeneic pancreas islet transplantation, the evidence includes a randomized controlled trial, case series, and systematic reviews. The relevant outcomes are overall survival, change in disease status, medication use, resource utilization, and treatment-related morbidity. Results of a 2018 randomized trial have suggested some reduction in the number of severe hypoglycemic incidence annually, but limited follow-up and other trial limitations reduce the certainty in conclusions drawn. A wide range of insulin independence has been reported in case series. There is conflicting evidence on whether allogeneic islet transplantation reduces long-term diabetic complications. Long-term comparative studies are required to determine the effects of allogeneic islet transplantation in type 1 diabetics. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Supplemental Information**

**Practice Guidelines and Position Statements**

**National Institute for Health and Care Excellence**

Guidance from the National Institute for Health and Care Excellence (2008) indicated the evidence on allogeneic pancreatic islet cell transplantation for type 1 diabetes has shown that serious procedure-related complications may occur, and the long-term immunosuppression required is associated with risk of adverse events. A related 2008 guidance addressed autologous islet cell transplantation for improved glycemic control after pancreatectomy and stated that studies have shown "some short-term efficacy, although most patients require insulin therapy in the long term..."
Islet Transplantation

Policy # 00007
Original Effective Date: 08/26/2002
Current Effective Date: 05/11/2020

Complications result mainly from the major surgery involved in pancreatectomy (rather than from the islet cell transplantation)."

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Medicare National Coverage**
Medicare covers pancreatic islet transplantation in patients with type 1 diabetes participating in a clinical trial sponsored by the National Institutes of Health. Partial pancreatic tissue transplantation or islet transplantation performed outside a clinical trial are not.

**Ongoing and Unpublished Clinical Trials**
Some currently ongoing and unpublished trials that might influence this review are listed in Table 1.

**Table 1. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02505893</td>
<td>Minimal Islet Transplant at Diabetes Onset (MITO)</td>
<td>6</td>
<td>May 2018 (last updated February 2018)</td>
</tr>
<tr>
<td>NCT00160732</td>
<td>Allogenic Islet Cell Transplantation</td>
<td>50</td>
<td>Oct 2025</td>
</tr>
</tbody>
</table>
Islet Transplantation

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00706420</td>
<td>Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen</td>
<td>20</td>
<td>Dec 2019</td>
</tr>
<tr>
<td>NCT00306098</td>
<td>Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression</td>
<td>40</td>
<td>May 2021</td>
</tr>
<tr>
<td>NCT01909245</td>
<td>Islet Cell Transplant for Type 1 Diabetes (TCD)</td>
<td>30</td>
<td>Jul 2021</td>
</tr>
<tr>
<td>NCT01974674</td>
<td>Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes (GRIIF)</td>
<td>19</td>
<td>Jan 2022</td>
</tr>
<tr>
<td>NCT01897688</td>
<td>A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients</td>
<td>40</td>
<td>Mar 2027</td>
</tr>
<tr>
<td>NCT00679042</td>
<td>Islet Transplantation in Type 1 Diabetic Patients Using the</td>
<td>36</td>
<td>Jul 2027</td>
</tr>
</tbody>
</table>
Islet Transplantation

Policy # 00007
Original Effective Date: 08/26/2002
Current Effective Date: 05/11/2020

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>University of Illinois at Chicago (UIC) Protocol</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References
Islet Transplantation

Policy #  00007
Original Effective Date:  08/26/2002
Current Effective Date:  05/11/2020

Islet Transplantation

Policy #  00007
Original Effective Date:  08/26/2002
Current Effective Date:  05/11/2020

https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=286&ncdver=1&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&KeyWord=islet+cell&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAABAAAAA

Policy History
Original Effective Date:  08/26/2002
Current Effective Date:  05/11/2020
08/15/2002  Medical Policy Committee review
08/26/2002  Managed Care Advisory Council approval
08/31/2004  Medical Director review
09/21/2004  Medical Policy Committee review. Format revision. No substance change to policy.
09/27/2004  Managed Care Advisory Council approval
09/07/2005  Medical Director review
09/22/2005  Quality Care Advisory Council approval
09/06/2006  Medical Director review
09/20/2006  Medical Policy Committee approval. No changes to policy guidelines.
09/05/2007  Medical Director review
09/19/2007  Medical Policy Committee approval. No change to coverage eligibility.
09/03/2009  Medical Policy Committee approval
09/16/2009  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
09/09/2010  Medical Policy Committee review
09/01/2011  Medical Policy Committee review
09/14/2011  Medical Policy Implementation Committee approval. No change to coverage statement.
09/06/2012  Medical Policy Committee review
Islet Transplantation

Policy #  00007
Original Effective Date:  08/26/2002
Current Effective Date:  05/11/2020

09/19/2012  Medical Policy Implementation Committee approval. Title changed to “Islet Transplantation”. The words pancreatic and cell were dropped from the coverage statements.
09/05/2013  Medical Policy Committee review
09/18/2013  Medical Policy Implementation Committee approval. No change to coverage.
09/04/2014  Medical Policy Committee review
08/03/2015  Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
09/03/2015  Medical Policy Committee approval
10/01/2016  Coding update
11/03/2016  Medical Policy Committee approval
01/01/2017  Coding update: Removing ICD-9 Diagnosis Codes
11/02/2017  Medical Policy Committee approval
11/08/2018  Medical Policy Committee review
11/07/2019  Medical Policy Committee review
04/02/2020  Medical Policy Committee review
04/08/2020  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date:  04/2021
Islet Transplantation

Policy # 00007
Original Effective Date: 08/26/2002
Current Effective Date: 05/11/2020

**Coding**

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2019 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0584T, 0585T, 0586T</td>
</tr>
<tr>
<td></td>
<td>Codes added eff 1/1/2020: 48160, 48999</td>
</tr>
<tr>
<td>HCPCS</td>
<td>G0341, G0342, G0343, S2102</td>
</tr>
</tbody>
</table>
Islet Transplantation

Policy # 00007
Original Effective Date: 08/26/2002
Current Effective Date: 05/11/2020


*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services.
Islet Transplantation

Policy # 00007
Original Effective Date: 08/26/2002
Current Effective Date: 05/11/2020

...at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.